4-Phenylpiperidine RBP4 Modulators for Bisretinoid Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no FDA-approved treatment for the dry form of age-related macular degeneration (AMD), a leading cause of blindness, due to the lack of effective pharmacological interventions targeting the cytotoxic bisretinoids that accumulate in the retinal pigment epithelium, which trigger photoreceptor degeneration.
Innovation Solution
Development of 4-phenylpiperidine compounds that inhibit the visual cycle partially, reducing the formation of cytotoxic bisretinoids like A2E, atRAL di-PE, and A2-DHP-PE, which are implicated in AMD and Stargardt Disease, by interacting with retinol-binding protein 4 (RBP4) and transthyretin (TTR) complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If partial pharmacological inhibition of the visual cycle is implemented, then accumulation of cytotoxic bisretinoids is reduced, but the visual cycle function is compromised
Solution Approach 1:
The patent modifies the visual cycle parameters by introducing compounds that selectively inhibit specific enzymatic steps (such as condensation of all-trans retinaldehyde with phosphatidylethanolamine) without completely blocking the cycle. This allows controlled reduction of harmful bisretinoid accumulation while maintaining sufficient visual function through partial inhibition rather than total blockade.
Solution Approach 2:
The patent converts the harmful by-product of the visual cycle (cytotoxic bisretinoids like A2E) into a target for therapeutic intervention. By designing inhibitors that specifically block the formation of these harmful compounds while allowing the essential visual cycle function to proceed, the harmful accumulation is transformed into a controllable parameter for disease treatment.
2Adaptability or versatility
If new pharmacological treatments are developed for dry AMD, then treatment options are expanded, but development time and complexity increase
Solution Approach 1:
The patent develops compounds with broad applicability that can treat multiple conditions (dry AMD, Stargardt disease, and other lipofuscin-related disorders) through a single mechanistic approach targeting the visual cycle. This multi-functional strategy accelerates development by eliminating the need for separate drug development programs for each condition.
Solution Approach 2:
The patent identifies and targets the formation of cytotoxic bisretinoids at an early stage in their accumulation process, rather than addressing advanced disease stages. By intervening preliminarily at the source of harmful compound formation, the treatment can prevent disease progression before significant damage occurs, reducing the time needed for therapeutic efficacy to manifest.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the accumulation of cytotoxic bisretinoids, potentially slowing down the progression of AMD and Stargardt Disease by targeting the visual cycle at its source, providing a novel therapeutic approach.
Implementation Method 1
inhibit the visual cycle partially, reducing the formation of cytotoxic bisretinoids like A2E, atRAL di-PE, and A2-DHP-PE, which are implicated in AMD and Stargardt Disease, by interacting with retinol-binding protein 4 (RBP4) and transthyretin (TTR) complexes
Data Source
AI summary
The present invention provides a compound having the structure:whereinR1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl;R6 is H, OH, or halogen;B is a substituted or unsubstituted heterobicycle,pyridazine, pyrazole, pyrazine, thiadiazole, or triazole,wherein the heterobicycle is other than chloro substituted indole; andthe pyrazole, when substituted, is substituted with other than trifluoromethyl,or a pharmaceutically acceptable salt theref.